SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (3494)11/5/2002 8:21:06 AM
From: Icebrg  Read Replies (1) | Respond to of 10345
 
Harold,

That is correct. Dr. Tracy suggested the following explanation about a year ago in a CNS regeneration review.

Erik

>>The sonic hedgehog program had been partnered with Biogen, but in mid-2000, Biogen suddenly surrendered its interest, returning the rights to Curis. This usually means either research failure or a retooling of corporate priorities. In this case, what we have heard was that Biogen's R&D group liked the sonic hedgehog program, but Biogen management did not like the fact that Biogen's ex-CEO James Tobin was a member of the new Curis Board, and chose to sever ties.>>



To: Harold Engstrom who wrote (3494)11/13/2002 10:25:15 AM
From: fred hayes  Read Replies (2) | Respond to of 10345
 
Harold, LGND is on sale today. I don't think this market looks past its short term nose. The value of Avinza has not yet been recognized by Ligand shareholders or the analysts who are busy downgrading Ligand today.

fred


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News